• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by PepGen Inc.

    8/13/25 9:02:13 PM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PEPG alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    PepGen Inc.

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)


    713317105

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    713317105


    1Names of Reporting Persons

    SUVRETTA CAPITAL MANAGEMENT, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    300,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    300,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    300,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.9 %
    12Type of Reporting Person (See Instructions)

    IA, OO


    SCHEDULE 13G

    CUSIP No.
    713317105


    1Names of Reporting Persons

    AVERILL MASTER FUND, LTD.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    300,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    300,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    300,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.9 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    CUSIP No.
    713317105


    1Names of Reporting Persons

    AARON COWEN
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    300,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    300,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    300,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.9 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    PepGen Inc.
    (b)Address of issuer's principal executive offices:

    1 Marina Park Drive, Suite 900, Boston, MA 02210
    Item 2. 
    (a)Name of person filing:

    Suvretta Capital Management, LLC Averill Master Fund, Ltd. Aaron Cowen
    (b)Address or principal business office or, if none, residence:

    Suvretta Capital Management, LLC 540 Madison Avenue, 7th Floor New York, New York 10022 United States of America Averill Master Fund, Ltd. c/o Maples Corporate Services Limited P.O. Box 309 Ugland House Grand Cayman KY1-1104 Cayman Islands Aaron Cowen c/o Suvretta Capital Management, LLC 540 Madison Avenue, 7th Floor New York, New York 10022
    (c)Citizenship:

    Suvretta Capital Management, LLC - Delaware Averill Master Fund, Ltd. - Cayman Islands Aaron Cowen - United States
    (d)Title of class of securities:

    Common Stock, par value $0.0001 per share
    (e)CUSIP No.:

    713317105
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Suvretta Capital Management, LLC - 300,000 Averill Master Fund, Ltd. - 300,000 Aaron Cowen - 300,000
    (b)Percent of class:

    Suvretta Capital Management, LLC - 0.9% Averill Master Fund, Ltd. - 0.9% Aaron Cowen - 0.9%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Suvretta Capital Management, LLC - 0 Averill Master Fund, Ltd. - 0 Aaron Cowen - 0

     (ii) Shared power to vote or to direct the vote:

    Suvretta Capital Management, LLC - 300,000 Averill Master Fund, Ltd. - 300,000 Aaron Cowen - 300,000

     (iii) Sole power to dispose or to direct the disposition of:

    Suvretta Capital Management, LLC - 0 Averill Master Fund, Ltd. - 0 Aaron Cowen - 0

     (iv) Shared power to dispose or to direct the disposition of:

    Suvretta Capital Management, LLC - 300,000 Averill Master Fund, Ltd. - 300,000 Aaron Cowen - 300,000

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    All of the securities reported in this Schedule 13G Amendment No. 1 are directly owned by advisory clients of Suvretta Capital Management, LLC. None of those advisory clients may be deemed to beneficially own more than 5% of the Common Stock, par value $0.0001 per share.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    Please see Exhibit B attached hereto.
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    SUVRETTA CAPITAL MANAGEMENT, LLC
     
    Signature:By: /s/ Andrew Nathanson
    Name/Title:Andrew Nathanson, General Counsel and Chief Compliance Officer
    Date:08/13/2025
     
    AVERILL MASTER FUND, LTD.
     
    Signature:By: /s/ Andrew Nathanson
    Name/Title:Andrew Nathanson, Authorized Signatory
    Date:08/13/2025
     
    AARON COWEN
     
    Signature:By: /s/ Aaron Cowen
    Name/Title:Aaron Cowen
    Date:08/13/2025

    Comments accompanying signature:  * Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his, her or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. To the extent that "ownership of 5 percent or less of a class" was indicated in Item 5, such response only applies to the Reporting Person(s) that indicated elsewhere herein that it beneficially owns five percent (5%) or less of the class.
    Exhibit Information

    [Exhibit A - Joint Filing Agreement] [Exhibit B - Control Person Identification]

    Get the next $PEPG alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PEPG

    DatePrice TargetRatingAnalyst
    12/16/2024$3.00Neutral → Underperform
    BofA Securities
    7/31/2024$12.00Buy → Neutral
    BofA Securities
    12/21/2022$26.00Buy
    H.C. Wainwright
    More analyst ratings

    $PEPG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PepGen Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

    – Last patient dosed in 15 mg/kg cohort of FREEDOM-DM1; on track to report topline data from study in early Q4 2025 – – FREEDOM to conclude with the 15 mg/kg cohort based on splicing and safety data observed to date; clinical sites will begin transitioning to the Phase 2 multiple ascending dose study, FREEDOM2-DM1 – PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results and recent corporate highlights for the quarter ended June 30, 2025. "This quarter, we made further progress in the develo

    8/7/25 8:00:00 AM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PepGen to Focus on Development of Promising DM1 Program Following 10 mg/kg PGN-EDO51 Update

    – PGN-EDO51 did not achieve target dystrophin levels in CONNECT1-EDO51 trial; Company to discontinue development of DMD programs – – PGN-EDO51 at 10 mg/kg was generally well tolerated; all treatment-related adverse events were mild – – DM1 program on track to read out FREEDOM-DM1 15 mg/kg cohort in second half of 2025 and FREEDOM2-DM1 5 mg/kg cohort in Q1 2026 – PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies, today announced that based on the levels of dystrophin protein measured in the 10 mg/kg cohort of its CONNECT1-EDO51 study investigating PGN-EDO51 in Duchenne muscular dystrophy (DMD) patients amenable

    5/28/25 4:05:00 PM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PepGen Appoints Kasra Kasraian, PhD, as Chief Technology Officer

    PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Kasra Kasraian, PhD, as Chief Technology Officer (CTO). Dr. Kasraian brings over 25 years of experience in product and process development, CMC strategy, and technical operations, spanning small and large molecules, as well as cell and gene therapies. "We are pleased to welcome Kasra to our executive leadership team," said James McArthur, PhD, President and Chief Executive Officer of PepGen. "He brings a rare depth of expertise in product

    5/20/25 7:00:00 AM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PEPG
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by PepGen Inc.

    SCHEDULE 13G/A - PepGen Inc. (0001835597) (Subject)

    8/13/25 9:02:13 PM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PepGen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - PepGen Inc. (0001835597) (Filer)

    8/7/25 8:02:23 AM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by PepGen Inc.

    10-Q - PepGen Inc. (0001835597) (Filer)

    8/7/25 8:00:21 AM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PEPG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    PepGen downgraded by BofA Securities with a new price target

    BofA Securities downgraded PepGen from Neutral to Underperform and set a new price target of $3.00

    12/16/24 12:07:01 PM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PepGen downgraded by BofA Securities with a new price target

    BofA Securities downgraded PepGen from Buy to Neutral and set a new price target of $12.00

    7/31/24 11:28:59 AM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on PepGen with a new price target

    H.C. Wainwright initiated coverage of PepGen with a rating of Buy and set a new price target of $26.00

    12/21/22 9:28:36 AM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PEPG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Head of R&D Streck Paul bought $10,393 worth of shares (8,375 units at $1.24), increasing direct ownership by 43% to 27,805 units (SEC Form 4)

    4 - PepGen Inc. (0001835597) (Issuer)

    6/2/25 5:03:19 PM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Mcarthur James G bought $13,550 worth of shares (10,000 units at $1.35), increasing direct ownership by 10% to 113,913 units (SEC Form 4)

    4 - PepGen Inc. (0001835597) (Issuer)

    4/22/25 7:01:12 AM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Mcarthur James G bought $47,725 worth of shares (41,500 units at $1.15), increasing direct ownership by 66% to 103,913 units (SEC Form 4)

    4 - PepGen Inc. (0001835597) (Issuer)

    4/9/25 7:40:15 AM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PEPG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Ra Capital Management, L.P.

    4 - PepGen Inc. (0001835597) (Issuer)

    6/6/25 8:43:35 AM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Mayer Howard

    4 - PepGen Inc. (0001835597) (Issuer)

    6/6/25 6:56:13 AM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Henson Heidi

    4 - PepGen Inc. (0001835597) (Issuer)

    6/6/25 6:54:26 AM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PEPG
    Financials

    Live finance-specific insights

    View All

    PepGen Announces Positive Initial Results, Including Robust Splicing Correction, from Ongoing FREEDOM-DM1 Trial in Patients with DM1

    – Significant mean splicing correction of 29.1% following a single dose of PGN-EDODM1 at 10 mg/kg – – PGN-EDODM1 observed to have favorable emerging safety profile – – Conference call scheduled today at 8:00 a.m. ET – PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced initial positive clinical data from the 5 and 10 mg/kg dose cohorts in the ongoing FREEDOM-DM1 Phase 1 trial investigating PGN-EDODM1 in myotonic dystrophy type 1 (DM1). "These results far exceeded our expectations for splicing correctio

    2/24/25 7:00:00 AM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PepGen Announces Positive Data from Low-Dose Cohort of PGN-EDO51 in Ongoing CONNECT1-EDO51 Phase 2 Clinical Trial for Treatment of Duchenne Muscular Dystrophy

    – PGN-EDO51 at 5 mg/kg was well tolerated, and all patients continued to long-term extension portion of trial. Dosing of second cohort at 10 mg/kg is ongoing – – Four doses of PGN-EDO51 at 5 mg/kg achieved mean exon skipping levels of 2.15% after three months of dosing – – PGN-EDO51 at 5 mg/kg showed mean muscle-adjusted dystrophin level of 1.49%, a 0.70% increase from baseline, after three months of dosing – – PGN-EDO51 at 5 mg/kg showed mean absolute dystrophin level of 0.61%, a 0.26% increase from baseline, after three months of dosing – – Conference call scheduled for 4:30 p.m. ET – PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation

    7/30/24 4:02:00 PM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PepGen to Host Fourth Quarter and Full Year 2022 Financial Results Call

    BOSTON, March 16, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, will report its fourth quarter and full year 2022 financial results and provide a corporate update on Thursday, March 23, 2023. PepGen's management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30pm ET. The event will be webcast live under the Events & Presentations section of the Investor Relations section of PepGen's website. A replay of the event will be archived

    3/16/23 8:00:00 AM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PEPG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by PepGen Inc.

    SC 13G/A - PepGen Inc. (0001835597) (Subject)

    11/14/24 4:31:29 PM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by PepGen Inc.

    SC 13G - PepGen Inc. (0001835597) (Subject)

    11/14/24 11:10:10 AM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by PepGen Inc.

    SC 13G/A - PepGen Inc. (0001835597) (Subject)

    11/12/24 8:57:04 AM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PEPG
    Leadership Updates

    Live Leadership Updates

    View All

    PepGen Appoints Kasra Kasraian, PhD, as Chief Technology Officer

    PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Kasra Kasraian, PhD, as Chief Technology Officer (CTO). Dr. Kasraian brings over 25 years of experience in product and process development, CMC strategy, and technical operations, spanning small and large molecules, as well as cell and gene therapies. "We are pleased to welcome Kasra to our executive leadership team," said James McArthur, PhD, President and Chief Executive Officer of PepGen. "He brings a rare depth of expertise in product

    5/20/25 7:00:00 AM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PepGen Announces Appointment of Two New Directors to its Board

    PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointments of Lisa Wyman and Mitchell H. Finer, PhD, to its Board of Directors. Ms. Wyman and Dr. Finer are industry veterans, each bringing decades of executive experience in the life sciences to the Company. "We are thrilled to welcome Lisa and Mitch to our Board of Directors," said James McArthur, PhD, President and CEO of PepGen. "Lisa's proven ability to scale manufacturing for mid- to late-stage clinical trials and guide clinical-stage companies

    3/31/25 4:05:00 PM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PepGen Appoints Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & Development

    PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & Development (R&D), effective immediately. Dr. Streck will join the PepGen Executive Team and will be responsible for leading the R&D organization. "We are very pleased that Paul is joining PepGen at such an important time for the Company," said James McArthur, Ph.D., President and CEO of PepGen. "Throughout his career, Paul has served in leadership roles across both l

    8/20/24 8:00:00 AM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care